围产期妇女舍曲林群体药代动力学模型:ConcePTION项目贡献
结果显示CYP2C19慢代谢者舍曲林清除率降低42%,母乳脂肪含量加倍使MPR增加95%;模拟婴儿日剂量中位数为6.9 μg/kg(母亲日剂量50 mg时),占体重调整母体剂量的0.95%,提示婴儿暴露量低。
要点
- CYP2C19慢代谢者舍曲林清除率降低42%,需关注母体暴露差异。
- 母乳脂肪含量加倍使MPR增加95%,影响乳汁药物浓度。
- 母亲日剂量50 mg时,模拟婴儿日剂量中位数6.9 μg/kg,占体重调整母体剂量0.95%。
核心结论
- 婴儿经胎盘和母乳对舍曲林的暴露量低,支持妊娠和哺乳期使用舍曲林。
主要发现
- CYP2C19慢代谢者舍曲林清除率较其他表型降低42%。
- 母乳脂肪含量加倍使MPR增加95%。
- 母亲日剂量50 mg时,模拟婴儿日剂量中位数6.9 μg/kg,占体重调整母体剂量的0.95%。
- 母亲日剂量25至150 mg时,脐带血浓度中位数范围为3.29至33.23 ng/mL。
临床怎么用
- 临床可参考CYP2C19基因型和母乳脂肪含量评估舍曲林暴露风险。
- 妊娠和哺乳期使用舍曲林时,婴儿暴露量低,可提供用药 reassurance。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sertraline is frequently prescribed for mental health conditions in both pregnant and breastfeeding women. According to the limited available data, only small amounts of sertraline are transferred into human milk, yet with a large amount of unexplained interindividual variability. This study aimed to develop a population pharmacokinetic (popPK) model to describe the pharmacokinetics of sertraline during the perinatal period and explain interindividual variability. METHODS: Pregnant women treated with sertraline were enrolled in the multicenter prospective cohort SSRI-Breast Milk study. A popPK model for sertraline maternal plasma and breast milk concentrations was developed and allowed estimating the milk-to-plasma ratio (MPR). An additional fetal compartment allowed cord blood concentrations to be described. Several covariates were tested for significance. Ultimately, model-based simulations allowed infant drug exposure through placenta and breast milk under various conditions to be predicted. RESULTS: Thirty-eight women treated with sertraline were included in the study and provided 89 maternal plasma, 29 cord blood and 107 breast milk samples. Sertraline clearance was reduced by 42% in CYP2C19 poor metabolizers compared to other phenotypes. Doubling milk fat content increased the MPR by 95%. Simulations suggested a median daily infant dosage of 6.9 μg kg-1 after a 50 mg maternal daily dose, representing 0.95% of the weight-adjusted maternal dose. Median cord blood concentrations could range from 3.29 to 33.23 ng mL-1 after maternal daily doses between 25 and 150 mg. CONCLUSIONS: Infant exposure to sertraline, influenced by CYP2C19 phenotype and breast milk fat content, remains low, providing reassurance regarding the use of sertraline during pregnancy and breastfeeding.
引用
- Monfort A, Cardoso E, Eap CB, et al. A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project. Br J Clin Pharmacol. 2024. PMID: 39030897. doi:10.1111/bcp.16177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。